Skip to content
OpenCapital
Get started

Nuvectis Pharma, Inc. NVCT Q1 2026 earnings

Reported May 5, 2026 · Before market open

EPS-$0.26Beat by $0.04
EPS estimate-$0.30

Next report

Aug 4, 2026 (In 5 days)
EPS estimate-$0.25

Financials

Q1 2026

Income statement

See full
Operating income-$6.3M-12.4%
Net income-$6.1M-13.5%
EPS (diluted)-$0.26+3.7%

Balance sheet

See full
Cash & equivalents$25.1M-15.9%
Total equity$14.2M-32.1%
Total assets$25.4M-15.8%

Cash flow

See full
Operating cash flow-$6.5M-56.0%

Valuation & ratios

Valuation

as of 07/28/26
See full
Market cap$616.01M+288%

Returns & leverage

See full
Return on equity-154.4%+79.4pp
Current ratio2.3×-1.0×

Versus estimates

Diluted EPS

Q1 2026-$0.26Beat by $0.04
Q4 2025-$0.31Miss by $0.05Q3 2025-$0.44Miss by $0.20Q2 2025-$0.30Miss by $0.05Q1 2025-$0.27Beat by $0.03Q4 2024-$0.36Miss by $0.08

Ask the moment Nuvectis Pharma, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Nuvectis Pharma, Inc. report Q1 2026 earnings?
Nuvectis Pharma, Inc. (NVCT) reported Q1 2026 earnings on May 5, 2026 before market open.
What were Nuvectis Pharma, Inc.'s Q1 2026 revenue and EPS?
Nuvectis Pharma, Inc. reported eps of $-0.26 for Q1 2026.
Did Nuvectis Pharma, Inc. beat estimates in Q1 2026?
EPS beat the consensus estimate of $-0.30 by $0.04.
How did Nuvectis Pharma, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 3.7% from $-0.27.
Where can I find Nuvectis Pharma, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001104659-26-055264) and the 10-Q periodic report (0001104659-26-055318) directly on SEC EDGAR. The filing index links above go to sec.gov.